Quantcast

Latest Roswell Park Cancer Institute Stories

2012-01-07 08:00:00

Simulated Surgical Systems announced that it has delivered one of its Robotic Surgery Simulators (RoSS) to the Karolinska University Hospital in Stockholm, Sweden. As a prerequisite to this delivery, the RoSS was successfully tested for CE compliance, paving the way for international sales. Williamsville, NY (PRWEB) January 07, 2012 The RoSS is the first simulator of its kind to feature training for complete surgical procedures. Its patented Hands on Surgical Training (HoST) modules use...

2012-01-05 14:42:06

In this small clinical trial, 53 percent of participants who used varenicline (Chantix) for four weeks before trying to quit were still tobacco-free three months later versus 40 percent of those who took varenicline as usually prescribed, for just one week before quitting. -- Among women, 67 percent of those who received the extra varenicline before quitting were still smoke-free at follow-up. -- As predicted, the extra weeks of medication allowed participants to reduce their smoking...

2011-06-25 00:00:30

S. 3988/A. 6233 will ensure that health plans already providing insurance coverage for chemotherapy will provide equal coverage for both IV/injected and oral therapies. The bill will be sent to the governor shortly. New York, NY (PRWEB) June 24, 2011 The New York Assembly voted unanimously 6/22/11 to pass S. 3988/A. 6233, a bill that will eliminate the disparity in insurance coverage between oral and intravenous chemotherapy therapies, ensuring that all cancer patients in the state have...

2011-06-23 07:30:00

BARCELONA, Spain, June 23, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented pre-clinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor...

2011-01-21 07:00:00

BUFFALO, N.Y., Jan. 21, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the...

2011-01-18 07:00:00

BUFFALO, N.Y., Jan. 18, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today announced that its lead compound, CFAK-C4 , which is in development for the treatment of pancreatic cancer, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). Orphan status is given to drugs and biologics that are being developed to...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related